# Kieran McCafferty

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/kieran-mccafferty/

## Facts

| Field | Value |
| --- | --- |
| Citations | 3,880 |
| Field | Dialysis and Renal Disease Management |
| h-index | 26 |
| i10-index | 49 |
| Last Known Institution | Queen Mary University of London |
| OpenAlex ID | https://openalex.org/A5027355791 |
| ORCID iD | 0000-0002-0762-2270 |
| Works | 168 |

## Researcher papers

- [Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study](https://scholariq.org/papers/physical-cognitive-and-mental-health-impacts-of-covid-19-after-hospitalisation/)
- [Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial](https://scholariq.org/papers/efficacy-and-safety-of-sparsentan-versus-irbesartan-in-patients-with-iga/)
- [Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial](https://scholariq.org/papers/sparsentan-in-patients-with-iga-nephropathy-a-prespecified-interim-analysis-from/)
- [Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy](https://scholariq.org/papers/results-from-part-a-of-the-multi-center-double-blind-randomized-placebo/)
- [Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis](https://scholariq.org/papers/finerenone-in-patients-with-chronic-kidney-disease-and-type-2-diabetes-by-sodium/)
- [Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy](https://scholariq.org/papers/finerenone-in-predominantly-advanced-ckd-and-type-2-diabetes-with-or-without/)
- [A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia](https://scholariq.org/papers/a-phase-3b-randomized-double-blind-placebo-controlled-study-of-sodium-zirconium/)
- [Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial](https://scholariq.org/papers/effects-of-dapagliflozin-on-mortality-in-patients-with-chronic-kidney-disease-a/)
- [Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial](https://scholariq.org/papers/impact-of-primary-kidney-disease-on-the-effects-of-empagliflozin-in-patients/)
- [Efficacy of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis of KALM-1 and KALM-2 Phase 3 Studies](https://scholariq.org/papers/efficacy-of-difelikefalin-for-the-treatment-of-moderate-to-severe-pruritus-in/)
- [Artesunate Alleviate Kidney Fibrosis by Restoring Klotho Protein and Suppressing Wnt/β-Catenin Signalling Pathway](https://scholariq.org/papers/artesunate-alleviate-kidney-fibrosis-by-restoring-klotho-protein-and-suppressing/)

## Researcher topics

- [Dialysis and Renal Disease Management](https://scholariq.org/topics/dialysis-and-renal-disease-management/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Urticaria and Related Conditions](https://scholariq.org/topics/urticaria-and-related-conditions/)

## Researcher university

- [Queen Mary University of London](https://scholariq.org/institutions/queen-mary-university-of-london/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.